<?xml version="1.0" encoding="UTF-8" standalone="no"?><information><Cell><NavigationPath><Head00>Dose level</Head00><Stub><StubValue>Total (n=27)</StubValue></Stub><HeaderValue>Total</HeaderValue></NavigationPath><value>16/27</value><CellType>Partially Numeric</CellType></Cell><Table><tableName>Outcome of treatment</tableName><TableType>Subheader</TableType><tableOrder>Table 5</tableOrder><tableFooter>CR=Complete response; PR=Partial response; NC=No change; PD=Progressive disease.</tableFooter></Table><Document><DocumentTitle>Phase Iâ€“II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer</DocumentTitle><PMC>2747698</PMC></Document></information>